Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$18.45 - $27.14 $335,531 - $493,568
18,186 New
18,186 $343,000
Q3 2022

Nov 14, 2022

BUY
$11.58 - $24.73 $2,084 - $4,451
180 Added 1.08%
16,912 $304,000
Q2 2022

Aug 11, 2022

BUY
$8.52 - $25.26 $142,556 - $422,650
16,732 New
16,732 $190,000

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $626M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.